html5-img
1 / 16

SOLVD (Studies of Left Ventricular Dysfunction)

SOLVD (Studies of Left Ventricular Dysfunction). Enalapril vs placebo in 6,794 patients Ejection fraction < 35% End points include: Delaying the progression of heart failure Improving signs and symptoms Reducing mortality

zihna
Télécharger la présentation

SOLVD (Studies of Left Ventricular Dysfunction)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SOLVD(Studies of Left Ventricular Dysfunction) • Enalapril vs placebo in 6,794 patients • Ejection fraction < 35% • End points include: • Delaying the progression of heart failure • Improving signs and symptoms • Reducing mortality • Treatment arm - 2,568 symptomatic class II-III patients most on digitalis and diuretics • Prevention arm - 4,226 asymptomatic class I-II patients, most on no concomitant therapy N Engl J Med 1991:325:293-302

  2. SOLVD Treatment TrialAll Cause Mortality 16% Risk Reduction p = 0.0036 N Engl J Med 1991;325:293-302

  3. Benefits of Enalapril • Patients: Symptomatic HF patients with LVD (EF < 35%) • Increased Survival • 32% at 3 months • 28% at 6 months • 21% at 12 months • 18% at 24 months • 12% at 36 months • 12% at 48 months • 11% reduction of overall mortality at end of study (P=0.0036) The SOLVD Investigators, N Engl J Med. 1991;325:293

  4. SOLVD Treatment TrialMortality or Hospitalization for CHF 26% Risk Reduction p<0.0001 N Engl J Med 1991;325:293-302

  5. SOLVD Treatment-Enalapril Symptomatic HF Patients with LVD (EF < 35%) (NYHA Class II-III) 30% Reduction p<0.001 971 683 Number of Hospitalizations Due to Heart failure The SOLVD Investigators, N Engl J Med, 1991

  6. SOLVD Treatment-Enalapril Symptomatic HF Patients with LVD (EF < 35%) (NYHA Class II-III) 33% Reduction p<0.001 234 157 Number of Readmissions for Heart failure The SOLVD Investigators, N Engl J Med, 1991

  7. SOLVD Treatment Trial • Implications: • Treating 1,000 patients for 3 years • Prevents about 50 deaths • Prevents about 350 hospitalizations

  8. Benefits of Enalapril • Patients: Symptomatic HF patients with LVD (EF < 35%) • Decreased hospitalizations • 48% at 3 months • 51% at 6 months • 46% at 12 months • 23% at 24 months • 28% at 36 months • 30% reduction of overall hospitalization at end of study (P<0.0001) • Convenient once - or twice - daily dosing The SOLVD Investigators, N Engl J Med. 1991;325:293

  9. SOLVD Treatment Trial Conclusions • Hospitalizations: • Risk reduced by 20% (p<0.001) • Significant reduction in CHF hospitalization by 1/3 (p<0.0001) • Sustained benefit over 4 years N Engl J Med 1991;325:293-302

  10. SOLVD Prevention TrialAll Cause Mortality Risk Reduction 8% P=0.30 N Engl J Med 1992;327:685-91

  11. SOLVD Prevention TrialDeath or Development of CHF Risk Reduction 29% p<0.001 N Engl J Med 1992;327:685-91

  12. SOLVD Prevention TrialFirst Hospitalization for CHF Risk Reduction 36% p<0.001 N Engl J Med 1992;327:685-91

  13. SOLVD Prevention Trial N Engl J Med 1992;327:685-91

  14. SOLVD Prevention- Enalapril Asymptomatic HF Patients w/ LVD (EF < 35%) (NYHA Class I-II) 32% Fewer First Hospitalizations p<0.001 273 184 Number of First Hospitalizations for Heart Failure The SOLVD Investigators, N Engl J Med, 1992.

  15. SOLVD Prevention TrialMorbidity and Combined Outcomes

  16. Enalapril - Dosing

More Related